22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
54 citations
,
November 1995 in “The Journal of Clinical Endocrinology & Metabolism” Females with 5 alpha-reductase-2 deficiency have less body hair, no acne, normal fertility, and delayed menarche.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
39 citations
,
April 2018 in “Hormones” No consistent link between genotype and phenotype in 5-α-Reductase type 2 deficiency.
October 2016 in “Letters in Drug Design & Discovery”
January 2020 in “Nihon Yakuri Gakkai nenkai yoshishu” Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.
55 citations
,
March 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
19 citations
,
June 2010 in “Journal of acupuncture and meridian studies” A plant extract was found to effectively block an enzyme related to male hormone-related diseases.
5α-reductase inhibitors are effective for treating hair loss in androgenetic alopecia.
45 citations
,
February 2005 in “Steroids” Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.
January 1978 in “Enlighten: Theses (The University of Glasgow)” Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
January 2009 in “ScholarlyCommons (University of Pennsylvania)” The P133R mutation in AKR1D1 enzyme causes harmful bile acid buildup, explaining related health issues.
3 citations
,
October 2010 in “Wiley-VCH Verlag GmbH & Co. KGaA eBooks” Finasteride safely treats enlarged prostate and male-pattern baldness.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
51 citations
,
July 2013 in “Brain Research” Testosterone needs to be converted to DHT to reduce stress response in male rats.
8 citations
,
March 2002 in “Archiv Der Pharmazie” The compound 4c effectively inhibits the enzyme linked to hair loss.
4 citations
,
September 2010 in “Medical Hypotheses”
3 citations
,
March 2016 in “Medicinal Chemistry Research” Scientists found out the structure of a human enzyme linked to prostate cancer and hair loss, which could help in designing drugs.
11 citations
,
November 2014 in “Behavior Genetics” 8 citations
,
March 2012 in “Mass spectrometry letters” The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.
12 citations
,
March 1995 in “Journal of the American Chemical Society” Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
July 2020 in “European urology open science” Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.